|
Condensed Consolidated Statements of Income (Unaudited) (USD $)
In Thousands, except Per Share data, unless otherwise specified |
3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
| Revenues: | ||||
| Product | $ 1,039,110 | $ 975,757 | $ 3,091,398 | $ 2,839,562 |
| Unconsolidated joint business | 287,792 | 266,471 | 856,975 | 739,054 |
| Other | 58,652 | 67,706 | 150,147 | 143,308 |
| Total revenues | 1,385,554 | 1,309,934 | 4,098,520 | 3,721,924 |
| Cost and expenses: | ||||
| Cost of sales, excluding amortization of acquired intangible assets | 139,358 | 123,527 | 411,666 | 327,143 |
| Research and development | 304,217 | 301,391 | 989,738 | 880,668 |
| Selling, general and administrative | 299,631 | 261,398 | 901,488 | 772,217 |
| Collaboration profit sharing | 75,545 | 81,475 | 239,951 | 244,319 |
| Amortization of acquired intangible assets | 53,013 | 49,347 | 151,256 | 157,699 |
| Fair value adjustment of contingent consideration | 9,456 | 2,500 | 23,573 | 5,900 |
| Restructuring charge | 803 | 1,803 | 2,225 | 18,390 |
| Total cost and expenses | 882,023 | 821,441 | 2,719,897 | 2,406,336 |
| Gain on sale of rights | 31,719 | 0 | 31,719 | 0 |
| Income from operations | 535,250 | 488,493 | 1,410,342 | 1,315,588 |
| Other income (expense), net | (4,548) | (7,727) | 13,546 | (9,504) |
| Income before income tax expense and equity in loss of investee, net of tax | 530,702 | 480,766 | 1,423,888 | 1,306,084 |
| Income tax expense | 131,044 | 127,104 | 334,213 | 339,608 |
| Equity in loss of investee, net of tax | 1,258 | 0 | 1,769 | 0 |
| Net income | 398,400 | 353,662 | 1,087,906 | 966,476 |
| Net income attributable to noncontrolling interests, net of tax | 0 | 1,836 | 0 | 32,286 |
| Net income attributable to Biogen Idec Inc. | $ 398,400 | $ 351,826 | $ 1,087,906 | $ 934,190 |
| Net income per share: | ||||
| Basic earnings per share attributable to Biogen Idec Inc. | $ 1.68 | $ 1.45 | $ 4.56 | $ 3.85 |
| Diluted earnings per share attributable to Biogen Idec Inc. | $ 1.67 | $ 1.43 | $ 4.53 | $ 3.81 |
| Weighted-average shares used in calculating: | ||||
| Basic earnings per share attributable to Biogen Idec Inc. | 236,474 | 242,883 | 238,331 | 242,266 |
| Diluted earnings per share attributable to Biogen Idec Inc. | 238,125 | 245,366 | 240,137 | 245,140 |
| X | ||||||||||
|
- Definition
Payments are made to Elan for their share of rest of world net operating profits to effect an equal sharing of collaboration operating profit. These payments include the reimbursement of our portion of third-party royalties that Elan pays on behalf of the collaboration, relating to sales outside of the U.S. These amounts are reflected in the collaboration profit sharing line in our consolidated statement of income. As sales of TYSABRI outside the U.S. increase, our collaboration profit sharing expense will increase. No definition available.
|
| X | ||||||||||
|
- Definition
Change in the fair value of potential payments under the contingent consideration arrangement including cash, included within the consolidated statements of income. No definition available.
|
| X | ||||||||||
|
- Definition
Gain on sale of our royalty and other rights related to future sales of BENLYSTA recognized in our consolidated statement of income. No definition available.
|
| X | ||||||||||
|
- Definition
Revenues from unconsolidated joint business consists of our share of pre-tax co-promotion profits in the U.S.; reimbursement of selling and development expense in the U.S.; and revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada. No definition available.
|
| X | ||||||||||
|
- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Total costs of sales and operating expenses for the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Sum of operating profit and nonoperating income or expense before Income or Loss from equity method investments, income taxes, extraordinary items, and noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
This item represents the entity's proportionate share for the period of the net income (loss) of its investee (such as unconsolidated subsidiaries and joint ventures) to which the equity method of accounting is applied. This item includes income or expense related to stock-based compensation based on the investor's grant of stock to employees of an equity method investee. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The sum of the current income tax expense or benefit and the deferred income tax expense or benefit pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount of Net Income (Loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The net result for the period of deducting operating expenses from operating revenues. No definition available.
|
| X | ||||||||||
|
- Definition
The net amount of other income and expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating income (expense) recognized for the period. Such amounts may include: (a) dividends, (b) interest on securities, (c) net gains or losses on securities, (d) unusual costs, (e) gains or losses on foreign exchange transactions, and (f) miscellaneous other income and expense items. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Revenues from the sale of other goods or rendering of other services, not elsewhere specified in the taxonomy; net of (reduced by) sales adjustments, returns, allowances, and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Amount charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, excluding asset retirement obligations. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
| X | ||||||||||
|
- Details
|
| X | ||||||||||
|
- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|